Company Overview
10x Genomics, Inc. operates as a specialized provider of instruments, consumables, and software solutions designed for the comprehensive analysis of biological systems across a global footprint that includes the United States, the rest of the Americas, Europe, the Middle East, Africa, China, and the Asia Pacific region. The company functions within the broader Healthcare sector, specifically targeting the Health Information Services industry, where it focuses on advancing genomic research and single-cell technologies. As of the latest reporting period, the organization supports a workforce of 1,178 employees and maintains a total market capitalization of $2.35 billion, while generating annual revenue of $642.82 million. These financial metrics indicate that 10x Genomics holds a significant market position within the genomic analysis space, commanding a valuation that reflects high investor expectations despite its current stage of profitability, as evidenced by a market cap that is nearly four times its trailing twelve-month revenue.
Financial Health
The company reported a revenue of $642.82 million over the trailing twelve months, yet it recorded a net income of -$43,544,000 and an EBITDA of -$64,086,000, revealing a substantial gap between top-line growth and bottom-line profitability that points to a cost structure dominated by high research and development expenses or operational inefficiencies. Despite the negative net income and EBITDA, the firm generated free cash flow of $148.39 million, which provides a critical buffer for financial flexibility by allowing the company to fund operations and strategic initiatives without relying heavily on external equity issuance. The margin profile shows a gross margin of 69.1%, indicating strong pricing power or cost control at the production level, contrasted sharply by an operating margin of -9.4% and a profit margin of -6.8%, which suggests that significant overhead costs are eroding profitability before interest and taxes. On the balance sheet, the company holds $523.41 million in cash against $84.36 million in debt, resulting in a debt-to-equity ratio of 10.59, which creates a complex picture where high leverage metrics coexist with substantial liquidity reserves. This liquidity is further supported by a current ratio of 4.46, signaling that the company possesses more than four times the current assets needed to cover its short-term liabilities and ensuring robust short-term solvency. Finally, the return on equity stands at -5.8% and the return on assets is -6.4%, metrics that indicate that management has not yet generated positive returns on shareholder capital or total assets, reflecting the capital-intensive nature of the business in its current growth phase.
Valuation Assessment
The valuation metrics present a distinct divergence between historical performance and future expectations, with a trailing P/E ratio listed as N/A due to the lack of recent net income, while the forward P/E is calculated at 112.59, implying that the market prices the stock based on anticipated future earnings rather than current results. The price-to-book ratio is 2.95, suggesting that the market values the company at nearly three times its book value, which typically indicates a premium assigned to the firm's intangible assets, intellectual property, and growth potential. Alternative valuation measures such as the price-to-sales ratio of 3.65 and an EV/EBITDA of -29.81 further highlight that the stock is being valued primarily on revenue generation rather than current cash earnings, as the negative EV/EBITDA underscores the absence of normalized earnings in the immediate term. In terms of trading range, the stock has fluctuated between a 52-week low of $6.78 and a 52-week high of $23.56, with the current price situated somewhere within this wide band, reflecting significant price volatility. The beta of 2.21 indicates that the stock is highly sensitive to market movements, tending to fluctuate with more than twice the magnitude of the broader market index, which increases both the potential for significant gains and the risk of substantial losses during periods of market turbulence.
Growth & Income
The revenue growth year-over-year is recorded at 0.6%, while earnings growth is listed as N/A, indicating that earnings are not currently expanding in tandem with revenue due to the company's ongoing losses. As a non-dividend payer, the company reports a dividend yield of N/A and a payout ratio of 0.0%, which confirms that all available earnings are being retained and reinvested into the business to fuel expansion rather than being distributed to shareholders. This strategy of retaining earnings is typical for high-growth technology companies that prioritize funding research and development over providing immediate income to investors. Overall, the growth and income profile of 10x Genomics, Inc. is characterized by modest revenue expansion and a complete reliance on retained earnings for capital allocation, with no current income distribution to complement the equity investment.